TORONTO, ONTARIO / ACCESSWIRE / December 13, 2024 / Quantum (NASDAQ:) BioPharma Ltd. (NASDAQ:QN™)(CSE:QN™)(FRA:0K91) (“Quantum BioPharma” or the “Company“), is happy to announce that it has closed an preliminary tranche (“First Tranche“) of the providing introduced on December 5, 2024 (the “December 5 NR“) and has issued 500 Debenture Models (as outlined within the December 5 NR) for $500,000.
The Firm will use the proceeds from the First Tranche for the continued improvement of the Firm’s enterprise mannequin and for common working capital functions.
All securities issued within the First Tranche are topic to a statutory maintain interval of 4 months and at some point from the date of issuance.
The Firm’s obligations below the Debentures (as outlined within the December 5 NR) are now not collaterally secured by common safety from the Firm.
All quantities on this press launch are expressed in Canadian {dollars}.
The securities being supplied haven’t been, nor will they be, registered below the US Securities Act of 1933, as amended, and will not be supplied or offered in the US or to, or for the account or advantage of, U.S. individuals absent registration or an relevant exemption from the registration necessities. This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase nor shall there be any sale of the securities in any State wherein such supply, solicitation or sale could be illegal.
About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical firm devoted to constructing a portfolio of modern property and biotech options for the therapy of difficult neurodegenerative and metabolic issues and alcohol misuse issues with drug candidates in numerous levels of improvement. By its wholly owned subsidiary, Lucid (NASDAQ:) Psycheceuticals Inc. (“Lucid“), Quantum BioPharma is targeted on the analysis and improvement of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity proven to forestall and reverse myelin degradation, the underlying mechanism of a number of sclerosis, in preclinical fashions. Quantum BioPharma invented UNBUZZD™ and spun out its OTC model to an organization, Celly Vitamin Corp. (“Celly Nutrition“), led by trade veterans. Quantum BioPharma retains possession of 25.71% (as of June 30, 2024) of Celly Vitamin at www.unbuzzd.com. The settlement with Celly Vitamin additionally consists of royalty funds of seven% of gross sales from unbuzzd™ till funds to Quantum BioPharma complete $250 million. As soon as $250 million is reached, the royalty drops to three% in perpetuity. Moreover, Quantum BioPharma retains a big tax loss carry ahead of roughly C$130 million and may very well be utilized sooner or later to offset tax payable obligations in opposition to future income. Quantum BioPharma retains 100% of the rights to develop comparable product or various formulations particularly for pharmaceutical and medical makes use of. Quantum BioPharma maintains a portfolio of strategic investments by way of its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or industrial property.
Ahead-Wanting Data
Sure data on this information launch constitutes forward-looking statements below relevant securities legal guidelines. Any statements which might be contained on this information launch that aren’t statements of historic reality could also be deemed to be forward-looking statements. Ahead-looking statements are sometimes recognized by phrases akin to “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the unfavorable of those phrases and comparable expressions. Ahead-looking statements on this information launch embrace statements regarding: the acknowledged phrases, use of proceeds, and timeline of the Providing; and the Firm’s issuance of the Debentures, Warrants (and the underlying Warrant Shares if exercised), and potential issuance of Shares (if the Debentures are transformed).
Ahead-looking data on this press launch are primarily based on sure assumptions and anticipated future occasions, together with however not restricted to: the Firm has the flexibility to hold out the Providing as acknowledged; and the Firm has the flexibility to situation the Debentures, Warrants (and the underlying Warrant Shares if exercised), and Shares (if the Debentures are transformed).
These statements contain identified and unknown dangers, uncertainties and different elements, which can trigger precise outcomes, efficiency or achievements to vary materially from these expressed or implied by such statements, together with however not restricted to: the Firm’s lack of ability to hold out the Providing as acknowledged; and the Firm’s lack of ability to situation the Debentures, Warrants (and the underlying Warrant Shares if exercised), and Shares (if the Debentures are transformed), as properly the reader is urged to discuss with further data regarding Quantum BioPharma, together with its annual data kind, might be situated on the SEDAR+ web site at www.sedarplus.ca and on the EDGAR part of the US Securities and Alternate Fee’s web site at www.sec.gov for a extra full dialogue of such danger elements and their potential results.
Readers are cautioned that the foregoing listing shouldn’t be exhaustive. Readers are additional cautioned to not place undue reliance on forward-looking statements, as there might be no assurance that the plans, intentions or expectations upon which they’re positioned will happen. Such data, though thought of affordable by administration on the time of preparation, could show to be incorrect and precise outcomes could differ materially from these anticipated.
Ahead-looking statements contained on this press launch are expressly certified by this cautionary assertion and replicate the Firm’s expectations as of the date hereof and are topic to alter thereafter. The Firm undertakes no obligation to replace or revise any forward-looking statements, whether or not on account of new data, estimates or opinions, future occasions or outcomes or in any other case or to clarify any materials distinction between subsequent precise occasions and such forward- trying data, besides as required by relevant legislation.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Government Co-Chairman of the Board
Electronic mail: Zsaeed@quantumbiopharma.com
Phone: (416) 854-8884
Investor Relations
Electronic mail: ir@quantumbiopharma.com, data@quantumbiopharma.com
Web site: www.quantumbiopharma.com
View the unique press launch on accesswire.com
